Monitor future press releases for additional payer agreements and quarterly test volume growth to gauge revenue ramp from expanded coverage. The 158 million covered lives figure provides a baseline for modeling potential utilization.
Price Chart
Executive Summary
Cerenome subsidiary CNSide Diagnostics signed an in-network provider agreement with Blue Cross Blue Shield of Michigan, effective September 1, 2026, covering the CNSide CSF Tumor Cell Enumeration assay. This brings total contracted reimbursement coverage to approximately 158 million commercial and Medicare Advantage covered lives, expanding patient access and strengthening the company's national reimbursement strategy.
Key Facts
- In-network provider agreement with Blue Cross Blue Shield of Michigan effective September 1, 2026
- BCBSM serves approximately 5 million commercial and Medicare Advantage members
- Total contracted reimbursement coverage now represents approximately 158 million covered lives
- More than 11,000 CNSide tests performed since 2020 at over 120 U.S. cancer institutions
- CNSide CSF Assay Platform supports diagnosis and treatment monitoring for leptomeningeal metastases
Financial Impact
Expanded commercial payer coverage to 158 million covered lives; no specific revenue or reimbursement rate disclosed
Risk Factors
- Reimbursement rates and actual test utilization may not materialize as expected
- Competition from alternative diagnostic methods or technologies
- Dependence on continued payer contracting and network participation
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3366175 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 25d ago | 8-K | $1.60 | awaiting T+20 | — | $1.60 (+0.00%) |
Sep 30, 2026 27d ago | Press Release | $1.87 | awaiting T+20 | — | $1.60 (−14.44%) |
Sep 22, 2026 5w ago | Press Release | $2.03 $1.68 | ▼ −17.24% | ▼ −16.68% | $1.60 (−21.18%) |
Sep 16, 2026 5w ago | Press Release | $2.04 $1.74 | ▼ −14.71% | ▼ −17.88% | $1.60 (−21.57%) |
Sep 10, 2026 6w ago | 8-K | $2.39 $1.79 | ▲ +25.10% | ▲ +27.23% | $1.60 (+33.05%) |
Aug 14, 2026 10w ago | Press Release | $3.20 $2.12 | ▲ +33.75% | ▲ +31.77% | $1.60 (+50.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers